Funded by The Charles Bronfman Institute for Personalized Medicine, BioMe is an electronic medical record-linked biobank that enables researchers to quickly and efficiently conduct genetic, epidemiologic, molecular, and genomic studies on large collections of research specimens linked with medical information. Rapid access to this resource positions the Mount Sinai Health System and its research groups at the vanguard of clinical and translational research in genomic medicine, pharmacogenomics, and personalized medicine.
BioMe Used in Many Medical Fields
BioMe is a vast, ongoing collection of de-identified DNA, plasma, clinical medical record and questionnaire data, and large-scale genome-wide genotype and exome-chip data. BioMe has enrolled more than 52,500 patients as of September 2019 and currently enrolls an average of 600 new patients each month. The Program for the Protection of Human Subjects at the Icahn School of Medicine regulates BioMe, which presents minimal risk for human subjects.
Our donors’ specimens and family health history questionnaires are linked to “living” medical records; they are not frozen at the time of BioMe enrollment but continually updated and evolving in real-time as a patient’s clinical data is collected. BioMe is used for different services spanning a number of medical fields, including Inflammatory Bowel Disease; hepatitis C and thyroiditis; abdominal aortic aneurysms; intracranial aneurysm (neurosurgery); chronic kidney disease; polycystic ovarian syndrome and infertility; gestational diabetes; pediatric allergies; gastric cancer; obesity; asthma and allergic rhinitis; multiple sclerosis, and more.